Want to see ELTX full AI Analyst Report?
ELTX Stock Chart & Stats
$13.55
$0.10(1.66%)
At close: 4:00 PM EST
$13.55
$0.10(1.66%)
Day’s Range― - ―
52-Week Range$2.66 - $16.00
Previous CloseN/A
Volume37.28K
Average Volume (3M)3.29M
Market Cap
$72.98M
Enterprise Value$194.08
Total Cash (Recent Filing)$14.95M
Total Debt (Recent Filing)$14.34M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Aug 07, 2026EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding23,466,394
10 Day Avg. Volume1,182,257
30 Day Avg. Volume3,290,530
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)74.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.30
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$20.67Price Target Upside52.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.13
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biological Activity & Biomarker LinkDemonstrated correlation between KRAS-specific T‑cell responses and better outcomes provides a durable mechanistic signal of target engagement and pharmacodynamic effect. This biomarker link supports patient selection strategies, can de‑risk registrational design in defined subgroups, and strengthens the platform's scientific rationale over months.
Potential Checkpoint SynergyObserved deep responses after subsequent PD‑1 therapy suggest ELI‑002 may prime tumors to respond to checkpoint inhibitors. If reproducible, this mechanistic synergy supports durable combination strategies, shortens development pathways in selected indications, and enhances the long‑term value of the AMP platform beyond monotherapy outcomes.
Recent $15M Registered OfferingA completed registered direct offering provides non‑dilutive‑per‑transaction runway relief and immediate funding to advance clinical programs. This financing supports near‑term development milestones and trial activities, reducing short‑term execution risk and enabling continued investment in the KRAS immunotherapy strategy across the coming quarters.
Bears Say
No Revenue; Persistent Net LossesAs a clinical‑stage biotech, the company generates no product revenue and incurs substantial recurring R&D and operating losses. Persistent large losses mean long lead times to commercialization and continual reliance on capital markets or partners, creating durable execution and sustainability risk until an approved therapy or recurring revenue source exists.
Heavy Cash Burn & Negative Free Cash FlowSustained negative operating and free cash flow of roughly -$38.5M TTM indicates the company will repeatedly need external capital to fund trials. Even with some stabilization, ongoing burn constrains strategic options, increases dilution risk, and makes multi‑year development plans contingent on successful fundraising or partnerships.
Weakened Balance Sheet & LeverageThe swing to negative equity and relatively high leverage reduce financial flexibility and elevate financing costs or dilution when raising capital. A small asset base (~$22.7M TTM) and strained capitalization limit the company's ability to absorb setbacks or fund larger registrational programs without less‑favorable partner or investor terms.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics, Inc’s price range in the past 12 months?
Elicio Therapeutics, Inc lowest stock price was $2.66 and its highest was $16.00 in the past 12 months.
What is Elicio Therapeutics, Inc’s market cap?
Elicio Therapeutics, Inc’s market cap is $72.98M.
When is Elicio Therapeutics, Inc’s upcoming earnings report date?
Elicio Therapeutics, Inc’s upcoming earnings report date is Aug 07, 2026 which is in 18 days.
How were Elicio Therapeutics, Inc’s earnings last quarter?
Elicio Therapeutics, Inc released its earnings results on May 11, 2026. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.465 by -$0.185.
Is Elicio Therapeutics, Inc overvalued?
According to Wall Street analysts Elicio Therapeutics, Inc’s price is currently Undervalued.
Does Elicio Therapeutics, Inc pay dividends?
Elicio Therapeutics, Inc does not currently pay dividends.
What is Elicio Therapeutics, Inc’s EPS estimate?
Elicio Therapeutics, Inc’s EPS estimate is -0.54.
How many shares outstanding does Elicio Therapeutics, Inc have?
Elicio Therapeutics, Inc has 23,466,394 shares outstanding.
What happened to Elicio Therapeutics, Inc’s price movement after its last earnings report?
Elicio Therapeutics, Inc reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.465. Following the earnings report the stock price went down -9.13%.
Which hedge fund is a major shareholder of Elicio Therapeutics, Inc?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.67 (52.52% Upside)
$20.67 (52.52% Upside)
Blogger Sentiment
Bearish
ELTX Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 12.0%
Last 30 Days ▲ 12.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.38%
Trailing 12-Months
Company Description
Elicio Therapeutics, Inc
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$20.67
▲(52.52% Upside)
Technical Analysis
Compugen
―
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
0.95% Insiders
2.68% Mutual Funds
0.04% Other Institutional Investors
91.40% Public Companies and
Individual Investors